K-Line Chart, actual market data is subject to the trading page.
Key Data
Prev. Open
$7.24
Prev. Close
$8.51
Prev. Day's Range
$7.17 - $8.55
52W Range
$6.53 - $24.27
Trading Volume
1.666M
MC
$414.013M
P/E Ratio
--
EPS
$-2.26
Company Overview
NASDAQ
Avalo Therapeutics Inc is a clinical-stage biotechnology company dedicated to innovating therapies for rare and underserved diseases, particularly in the realm of immunological regulation. The company boasts a strong pipeline of proprietary drug candidates that target serious conditions characterized by significant unmet medical needs, underscoring its commitment to advancing healthcare solutions. Leveraging its extensive expertise in disease mechanisms and thorough clinical trial methodologies, Avalo is strategically positioned to develop transformative therapies. By maintaining a strong focus on patient-centric approaches, Avalo aims to enhance therapeutic outcomes and create meaningful changes in patients' lives, reflecting its potential to make a profound impact in the biopharmaceutical sector.
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
Headquarters1500 LIBERTY RIDGE DRIVE, WAYNE, PA, UNITED STATES, 19087
AVTX, known as Avalo Therapeutics, operates in the biotechnology sector with a focus on developing and commercializing therapies for rare diseases and immune system disorders. The company aims to address unmet medical needs through innovative research and product development efforts.
The primary revenue drivers for Avalo Therapeutics include the sale and licensing of its proprietary therapies and pharmaceutical products, along with collaboration agreements. Additionally, revenues may be supplemented through funding and milestone payments tied to clinical development partnerships.
Investors in AVTX face risks such as the lengthy and costly drug development process, regulatory uncertainty, competition from other biotech firms, and potential delays or failures in clinical trials. Furthermore, volatility in biotech stocks can impact returns, and the company might require additional capital to support development stages.
Avalo Therapeutics competes with other biotechnology companies specializing in rare diseases and immune system disorders. Competitors may include established players like Regeneron Pharmaceuticals and smaller firms developing niche therapeutics targeting similar indications, depending on overlapping drug pipelines.
Avalo Therapeutics does not pay dividends. As a biotech company focused on research and development, its financial resources are typically reinvested into advancing drug pipelines and supporting operational growth rather than distributing earnings as dividends.
Avalo Therapeutics provides potential upside for investors through its focus on addressing unmet medical needs in rare diseases and immune disorders, areas with high demand for innovative treatments. Successful clinical trials, regulatory approvals, and partnerships could enhance the company’s growth trajectory. However, investors should also weigh development risks.
AVTX's valuation is influenced by its development pipeline, clinical success potential, and market expectations. Compared to larger, established biotech firms, AVTX may trade at a lower valuation due to its smaller scale and higher risks. Investors should analyze its financials and clinical progress to assess its relative value.
Regulatory approvals are critical for Avalo Therapeutics as they determine its ability to market pharmaceutical products. Successful approvals can unlock substantial revenue opportunities and boost investor confidence, while delays or rejections in the regulatory process may negatively impact stock performance and future development funding.
Risk Warning
1.Stock prices may fluctuate significantly; invest with caution. Past performance is not indicative of future results.
2.Digital asset trading involves multiple risks, including market and technical risks. Please make rational decisions and allocate assets wisely.
3.The information contained on this page is for reference only and does not constitute any investment advice.
Transfer
